Related Experiment Video
Updated: Jun 22, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal
Zachary S Morris1, Andrea I McClatchey
1Massachusetts General Hospital Center for Cancer Research and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA.
Abstract:
The epidermal growth factor receptor (EGFR) has frequently been implicated in hyperproliferative diseases of renal tubule epithelia. We have shown that the NF2 tumor suppressor Merlin inhibits EGFR internalization and signaling in a cell contact-dependent manner. Interestingly, despite the paucity of recurring mutations in human renal cell carcinoma (RCC), homozygous mutation of the NF2 gene is found in approximately 2% of RCC patient samples in the Sanger COSMIC database. To examine the roles of Merlin and EGFR in kidney tumorigenesis, we generated mice with a targeted deletion of Nf2 in the proximal convoluted epithelium using a Villin-Cre transgene. All of these mice developed intratubular neoplasia by 3 months, which progressed to invasive carcinoma by 6-10 months. Kidneys from these mice demonstrated marked hyperproliferation and a concomitant increase in label-retaining putative progenitor cells. Early lumen-filling lesions in this model exhibited hyperactivation of EGFR signaling, altered solubility of adherens junctions components, and loss of epithelial polarity. Renal cortical epithelial cells derived from either early or late lesions were dependent on EGF for in vitro proliferation and were arrested by pharmacologic inhibition of EGFR or re-expression of Nf2. These cells formed malignant tumors upon s.c. injection into immunocompromised mice before in vitro passage. Treatment of Vil-Cre;Nf2(lox/lox) mice with the EGFR inhibitor erlotinib halted the proliferation of tumor cells. These studies give added credence to the role of EGFR signaling and perhaps Nf2 deficiency in RCC and describe a rare and valuable mouse model for exploring the molecular basis of this disease.
Insights
NF2 deficiency in kidney cells drives cancer by activating EGFR signaling. Inhibiting EGFR with erlotinib halts tumor growth in a new mouse model, offering insights into renal cell carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Nephrology
Background:
- Epidermal growth factor receptor (EGFR) is implicated in kidney tubule hyperproliferative diseases.
- The NF2 tumor suppressor Merlin inhibits EGFR signaling in a cell contact-dependent manner.
- NF2 mutations are found in a small percentage of renal cell carcinoma (RCC) cases.
Purpose of the Study:
- To investigate the roles of Merlin and EGFR in kidney tumorigenesis.
- To develop and characterize a novel mouse model for studying RCC.
Main Methods:
- Generated mice with targeted deletion of Nf2 in proximal convoluted epithelium using Villin-Cre.
- Analyzed tumor progression, cell proliferation, EGFR signaling, and epithelial polarity.
- Assessed tumor cell dependency on EGF and response to EGFR inhibition (erlotinib).
Main Results:
- Mice lacking Nf2 in kidney epithelium developed invasive carcinoma with hyperproliferation and increased progenitor cells.
- Early tumors showed hyperactivated EGFR signaling, altered adherens junctions, and loss of polarity.
- Nf2-deficient kidney cells were EGF-dependent and sensitive to EGFR inhibition or Nf2 re-expression.
- EGFR inhibition with erlotinib halted tumor cell proliferation in vivo.
Conclusions:
- NF2 deficiency contributes to kidney tumorigenesis through EGFR hyperactivation.
- This mouse model is valuable for studying RCC molecular mechanisms.
- EGFR signaling is a potential therapeutic target in NF2-associated RCC.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation

